- Home
- VKTX vs AMLX Comparison
VKTX vs AMLX Comparison
Compare VKTX & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VKTX | AMLX |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.8B |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VKTX | AMLX |
|---|---|---|
| Price | $30.79 | $28.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 20 | 12 |
| Target Price | ★ $94.82 | $42.36 |
| AVG Volume (30 Days) | ★ 6.2M | 1.2M |
| Earning Date | 10-21-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $380,786,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1612.94 |
| 52 Week Low | $25.77 | $10.83 |
| 52 Week High | $43.15 | $41.14 |
Technical Indicators
Market Signals| Indicator | VKTX | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 47.15 | 41.55 |
| Support Level | $29.52 | $12.97 |
| Resistance Level | $35.47 | $34.35 |
| Average True Range (ATR) | 2.30 | 1.41 |
| MACD | -0.06 | -0.72 |
| Stochastic Oscillator | 27.41 | 10.81 |
Price Performance
Historical ComparisonAbout VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.